

IN THE CLAIMS

Claims 1-63 (canceled).

64. (previously presented) A method of producing a therapeutic adhesive formulation for use in a transdermal patch comprising the steps of: selecting an acrylic polymeric adhesive which is suitable for use with highly plasticizing drugs based upon it's content of between about 40% and about 90% of a C₄-C₁₂ alkyl acrylate and between about 10% and about 40% by weight of a C₁-C₄ alkyl acrylate hardening monomer; and mixing said acrylic polymeric adhesive with a highly plasticizing drug in an amount of between about 3% and about 65% by weight based on the weight of said mixture.

65-93. (canceled).

94. (previously presented) A therapeutic adhesive formulation comprising between about 65% and about 97% by weight of an acrylic polymeric adhesive which includes between about 40% and about 90% of a C₄-C₁₂ alkyl acrylate; between about 10% and about 40% by weight of a C₁-C₃ alkyl acrylate hardening monomer; between about 1% and about 20% by weight of a functionalizing monomer which facilitates crosslinking; and between about 3% and about 35% by weight of said mixture, of a highly plasticizing drug component.

95. (previously presented) The therapeutic adhesive formulation of claim 94 wherein said highly plasticizing drug component comprises a liquid drug component.

96. (previously presented) The therapeutic adhesive formulation of claim 94 wherein said highly plasticizing drug component comprises a solid drug component dissolved in a plasticizing solvent.

97. (previously presented) The therapeutic adhesive formulation of claim 96 wherein solid drug comprises a drug selected from the group consisting of propranolol, ketorolac,

buprenorphine, scopolamine, terbutaline, clonidine, morphine, terazosin, prazosine, diltiazem, verapamil, and ciproflaxocin.

98. (previously presented) The therapeutic adhesive formulation of claim 97 wherein said plasticizing solvent comprises a nonaqueous plasticizing solvent.

99. (previously presented) The therapeutic adhesive formulation of claim 96 wherein said C₄-C₁₂ alkyl acrylate is selected from the group consisting of 2-ethylhexyl acrylate, butyl acrylate, n-decyl, n-nonyl, 2-ethyloctyl, isooctyl and dodecyl acrylate.

100. (previously presented) The therapeutic adhesive formulation of claim 96 wherein said C₄-C₁₂ alkyl acrylate is provided in an amount of between about 60% and about 80% by weight based on the weight of said adhesive.

101-102 (canceled).

103. (previously presented) A therapeutic adhesive formulation comprising an acrylic polymeric adhesive which includes between about 40% and about 90% of a C₄-C₁₂ alkyl acrylate; between about 10% and about 40% by weight of a C₁-C₃ alkyl acrylate hardening monomer; between about 1% and about 15% by weight of a functionalizing monomer which facilitates crosslinking; and a therapeutically effective amount of a highly plasticizing drug component, wherein said blend is substantially anhydrous.

104-105 (canceled).

106. (previously presented) The therapeutic adhesive formulation of claim 101 wherein said highly plasticizing drug component comprises a liquid drug component.

107. (previously presented) The therapeutic adhesive formulation of claim 103 wherein said highly plasticizing drug component comprises a solid drug component dissolved in a plasticizing solvent.

108. (previously presented) The therapeutic adhesive formulation of claim 107 wherein said solid drug comprises a solid drug selection from the group consisting of propranolol, ketorolac, buprenorphine, scopolamine, terbutaline, clonidine, morphine, terazosin, prazosine, diltiazem, verapamil, and ciproflaxocin.

109. (previously presented) The therapeutic adhesive formulation of claim 108 wherein said plasticizing solvent comprises a nonaqueous plasticizing solvent.

110-113 (canceled).

114. (previously presented) A therapeutic adhesive formulation comprising between about 65% and about 97% by weight of an acrylic polymeric adhesive which includes a C₄-C₁₂ alkyl acrylate and a C₁-C₃ alkyl acrylate hardening monomer, and between about 3% and about 35% by weight based on the weight of said mixture of a highly plasticizing drug.

115-117(canceled).

118. (previously presented) The therapeutic adhesive formulation of claim 117 wherein said plasticizing solvent comprises a nonaqueous plasticizing solvent.

119-121 (canceled).